Enzalutamide + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Metastatic Prostate Cancer
Conditions
Progressive Metastatic Prostate Cancer
Trial Timeline
Apr 23, 2014 → Jul 17, 2024
NCT ID
NCT02294461About Enzalutamide + Placebo
Enzalutamide + Placebo is a phase 3 stage product being developed by Astellas Pharma for Progressive Metastatic Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02294461. Target conditions include Progressive Metastatic Prostate Cancer.
What happened to similar drugs?
2 of 20 similar drugs in Progressive Metastatic Prostate Cancer were approved
Approved (2) Terminated (4) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02677896 | Phase 3 | Completed |
| NCT02528643 | Phase 2 | Completed |
| NCT02294461 | Phase 3 | Completed |
| NCT02003924 | Phase 3 | Completed |
| NCT01212991 | Phase 3 | Completed |
| NCT00974311 | Phase 3 | Completed |
Competing Products
20 competing products in Progressive Metastatic Prostate Cancer